Skip to main content
Top
Gepubliceerd in: Tijdschrift voor Kindergeneeskunde 4/2007

01-08-2007 | Artikelen

Gevolgen ssri-gebruik zwangeren bij de pasgeborene in de eerste 48 uur post partum

Auteurs: Drs. T. P. H. Scheffers, J. G. van Enk

Gepubliceerd in: Tijdschrift voor Kindergeneeskunde | Uitgave 4/2007

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Het gebruik van ssri's (specifieke serotonineheropnameremmers) gedurende het derde trimester van de zwangerschap komt regelmatig voor en kan bij de pasgeborene leiden tot onttrekkingsverschijnselen. Dit onderzoek beschrijft het klachtenpatroon dat bij neonaten kan optreden wanneer de moeder tijdens de zwangerschap ssri's gebruikt. Bij een hoog percentage (62%) van in totaal 29 geobserveerde pasgeborenen werden in de eerste 48 uur post partum afwijkingen passend bij onttrekkingsverschijnselen geconstateerd. Bij 17% van de kinderen was daarbij een observatieperiode van langer dan 48 uur noodzakelijk. 45% van de bevallingen was niet fysiologisch. Slechts zes kinderen (21%) werden én fysiologisch geboren én hadden geen onttrekkingsverschijnselen. Wij adviseren de partus poliklinisch te laten plaatsvinden en de pasgeborene ten minste 48 uur te observeren bij maternaal ssri-gebruik in het laatste trimester van de zwangerschap.
Literatuur
go back to reference Lattimore KA, Donn SM, Kaciroti N, et al. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol. 2005;25(9):595-604.CrossRefPubMed Lattimore KA, Donn SM, Kaciroti N, et al. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol. 2005;25(9):595-604.CrossRefPubMed
go back to reference Ferreira E, Carceller AM, Agogue C, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics. 2007;119(1):52-9.CrossRefPubMed Ferreira E, Carceller AM, Agogue C, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics. 2007;119(1):52-9.CrossRefPubMed
go back to reference Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365(9458): 482-7.PubMed Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365(9458): 482-7.PubMed
go back to reference Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63 (8):898-906.CrossRefPubMed Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63 (8):898-906.CrossRefPubMed
go back to reference Nordeng H, Spigset O. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant [review]. Drug Saf. 2005;28(7):565-81.CrossRefPubMed Nordeng H, Spigset O. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant [review]. Drug Saf. 2005;28(7):565-81.CrossRefPubMed
go back to reference Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications [review]. JAMA. 2005;293(19):2372-83.CrossRefPubMed Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications [review]. JAMA. 2005;293(19):2372-83.CrossRefPubMed
go back to reference Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 2001;90(3):288-91.CrossRefPubMed Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 2001;90(3):288-91.CrossRefPubMed
go back to reference Moor RA de, Mourad L, Haar J ter, Egberts AC. Onthoudingsverschijnselen bij een neonatus na blootstelling aan venlafaxine tijdens de zwangerschap. Ned Tijdschr Geneeskd. 2003;147(28):1370-2.PubMed Moor RA de, Mourad L, Haar J ter, Egberts AC. Onthoudingsverschijnselen bij een neonatus na blootstelling aan venlafaxine tijdens de zwangerschap. Ned Tijdschr Geneeskd. 2003;147(28):1370-2.PubMed
go back to reference Bot P, Semmekrot BA, Stappen J van der. Neonatal effects of exposure to selective serotonin reuptake inhibitors during pregnancy. Arch Dis Child Fetal Neonatal Ed. 2006;91(2): F153.CrossRefPubMed Bot P, Semmekrot BA, Stappen J van der. Neonatal effects of exposure to selective serotonin reuptake inhibitors during pregnancy. Arch Dis Child Fetal Neonatal Ed. 2006;91(2): F153.CrossRefPubMed
go back to reference Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998;279(8):609-10.CrossRefPubMed Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998;279(8):609-10.CrossRefPubMed
go back to reference Alwan S, Reefhuis J, Rasmussen S, et al. Maternal use of selective serotonin re-uptake inhibitors and risk for birth defects. Birth Defects Res A Clin Mol Teratol. 2005;731:291. Alwan S, Reefhuis J, Rasmussen S, et al. Maternal use of selective serotonin re-uptake inhibitors and risk for birth defects. Birth Defects Res A Clin Mol Teratol. 2005;731:291.
go back to reference Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol. 2006;21(3):221-2.CrossRefPubMed Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol. 2006;21(3):221-2.CrossRefPubMed
go back to reference Chambers CD, Hernandez-Diaz S, Marter LJ van, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6): 579-87.CrossRefPubMed Chambers CD, Hernandez-Diaz S, Marter LJ van, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6): 579-87.CrossRefPubMed
go back to reference Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 2003;142(4):402-8.CrossRefPubMed Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 2003;142(4):402-8.CrossRefPubMed
go back to reference Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry. 2002;159(11):1889-95.CrossRefPubMed Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry. 2002;159(11):1889-95.CrossRefPubMed
go back to reference Cissoko H, Swortfiguer D, Giraudeau B, et al. Exposition aux antidépresseurs inhibiteurs de la recapture de la sérotonine (IRS) en fin de grossesse: retentissement néonatal. Arch Pediatr. 2005;12(7):1081-4.CrossRefPubMed Cissoko H, Swortfiguer D, Giraudeau B, et al. Exposition aux antidépresseurs inhibiteurs de la recapture de la sérotonine (IRS) en fin de grossesse: retentissement néonatal. Arch Pediatr. 2005;12(7):1081-4.CrossRefPubMed
go back to reference Stiskal JA, Kulin N, Koren G, et al. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Ed. 2001;84(2):F134-5.CrossRefPubMed Stiskal JA, Kulin N, Koren G, et al. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Ed. 2001;84(2):F134-5.CrossRefPubMed
go back to reference Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003; 60(7):720-6.CrossRefPubMed Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003; 60(7):720-6.CrossRefPubMed
go back to reference Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160(2):173-6.CrossRefPubMed Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160(2):173-6.CrossRefPubMed
Metagegevens
Titel
Gevolgen ssri-gebruik zwangeren bij de pasgeborene in de eerste 48 uur post partum
Auteurs
Drs. T. P. H. Scheffers
J. G. van Enk
Publicatiedatum
01-08-2007
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Tijdschrift voor Kindergeneeskunde / Uitgave 4/2007
Print ISSN: 0376-7442
Elektronisch ISSN: 1875-6840
DOI
https://doi.org/10.1007/BF03061685

Andere artikelen Uitgave 4/2007

Tijdschrift voor Kindergeneeskunde 4/2007 Naar de uitgave

Casuïstische mededeling

Rhinovirusinfectie